Insider trade

Officer sold ~$770K of JAZZ shares in the open market

Traded Dec 5, 2025 · Filed Dec 10, 2025

Why it stands out

Jazz Pharmaceuticals's SVP, Chief Accounting Officer sold $770K of Jazz Pharmaceuticals shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$500K–$1M

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$770,405

Shares × reported transaction price

Timing vs results

30 days after results of Nov 5, 2025, 38 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	0.0%	−2.4%	+2.3%
30 days	−2.3%	+0.9%	−3.3%
90 days	+12.7%	−1.5%	+14.2%
180 days	+40.7%	+7.5%	+33.1%

Past results only. Not a forecast.

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $171.2001 to $171.2601. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.